- Reference code :
- wf342
- Published date :
-
08 September 2000
- Expired date :
-
25 January 2028
AstraZeneca today announced that it has filed a lawsuit in New York against Mylan Laboratories Inc. and Mylan Pharmaceuticals Inc. (Mylan) for patent infringement.
The lawsuit is the result of an Abbreviated New Drug Application (ANDA) filed by Mylan with the Food and Drug Administration (FDA) concerning its intent to market a generic omeprazole product in the US. The antisecretory drug omeprazole is marketed in the US by AstraZeneca, L.P. under the brand name Prilosec® and is marketed internationally by AstraZeneca as Losec®.
The basis for AstraZeneca's complaint is that the action by Mylan infringes upon several patents relating to Prilosec®, which provide protection to the year 2014. These patents include coverage for formulations and for methods of using Prilosec®. The substance patent, which expires in 2001, has not been challenged by Mylan.
AstraZeneca intends to fully enforce its patent rights and is steadfast in its belief that all of the patents are valid.
Further enquires to:
|
Steve Brown +44 (0)20 7304 5033 Lucy Williams +44 (0)20 7304 5034 Rachel Bloom 001 302 886 7858 |
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 06:58 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
